{"id":41828,"date":"2019-02-09T17:51:51","date_gmt":"2019-02-09T12:21:51","guid":{"rendered":"https:\/\/blog.forumias.com\/?p=41828"},"modified":"2019-02-09T17:51:51","modified_gmt":"2019-02-09T12:21:51","slug":"tb-survivors-challenge-patent-to-end-jj-monopoly","status":"publish","type":"post","link":"https:\/\/forumias.com\/blog\/tb-survivors-challenge-patent-to-end-jj-monopoly\/","title":{"rendered":"TB survivors challenge patent to end J&#038;J monopoly"},"content":{"rendered":"<p><strong><a href=\"https:\/\/www.thehindu.com\/news\/cities\/mumbai\/tb-survivors-challenge-patent-to-end-jj-monopoly\/article26218958.ece\">TB survivors challenge patent to end J&amp;J monopoly<\/a> <\/strong><\/p>\n<ol>\n<li>In an attempt to ensure that anti-TB drug Bedaquiline \u2013 which is safer and more effective \u2013is made affordable and accessible to everybody with drug resistant TB (DR-TB),\u00a0 two tuberculosis survivors from India and South Africa have filed a patent challenge against Johnson and Johnson\u2019s application to extend the patent over the drug.<\/li>\n<li>Bedaquiline is a drug used to treat TB patients with bacteria that are resistant to other anti-TB drugs and thus suffer from multidrug-resistant tuberculosis (MDR-TB).<\/li>\n<li>The J&amp;J patent application is being challenged on the grounds that the new salt form of Bedaquiline, does not merit patenting under India\u2019s Patents Act, 1970 as it is a minor reformulation of the drug without any increase in therapeutic efficacy and is a mere act of patent evergreening.<\/li>\n<li>In India, the high price of Bedaquiline is a significant barrier for the government to make it available to all patients with drug resistant TB thus exposing patients to less effective drugs with severe side effects.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>TB survivors challenge patent to end J&amp;J monopoly In an attempt to ensure that anti-TB drug Bedaquiline \u2013 which is safer and more effective \u2013is made affordable and accessible to everybody with drug resistant TB (DR-TB),\u00a0 two tuberculosis survivors from India and South Africa have filed a patent challenge against Johnson and Johnson\u2019s application to&hellip; <a class=\"more-link\" href=\"https:\/\/forumias.com\/blog\/tb-survivors-challenge-patent-to-end-jj-monopoly\/\">Continue reading <span class=\"screen-reader-text\">TB survivors challenge patent to end J&#038;J monopoly<\/span><\/a><\/p>\n","protected":false},"author":61,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":""},"categories":[555],"tags":[],"class_list":["post-41828","post","type-post","status-publish","format-standard","hentry","category-test-1","entry"],"jetpack_featured_media_url":"","views":{"total":0,"cached_at":"","cached_date":1704834568},"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/posts\/41828","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/users\/61"}],"replies":[{"embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/comments?post=41828"}],"version-history":[{"count":0,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/posts\/41828\/revisions"}],"wp:attachment":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/media?parent=41828"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/categories?post=41828"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/tags?post=41828"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}